Positions

Overview

  • Introduction:

    I completed medical school in India. After a short break to recover from Hodgkins lymphoma, I worked as a primary care physician and an internist in India. I subsequently moved to the United States and went on to complete a residency in Internal Medicine at Medstar Franklin Square Hospital in Baltimore, MD and a Hematology and Oncology fellowship at East Carolina University in Greenville, NC with a focus on thoracic malignancies. During the fellowship I developed an interest in drug development which led me to an Investigational Cancer Therapeutics fellowship at UT MD Anderson Cancer Center.

    Clinical Interests & Research:

    I am now an Assistant Professor of Medicine at The University of Alabama at Birmingham where I am in the process of building the lung cancer clinical trials portfolio and am the founder/lead of the immune related adverse events working group. My goal for the next 5 years is to build a diverse and meaningful clinical trial portfolio at UAB for our patients with thoracic malignancies, spanning from early stage disease to subsequent line therapies for those with metastatic disease. Additionally, I want to introduce biomarker-driven therapeutic trials to mitigate immune related adverse events.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Survival Is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving It Concurrently or AfterFrontiers in Oncology.  12. 2022
    2022 Non-Small Cell Lung Cancer, Version 3.2022 2022
    2022 Management of Immunotherapy-Related Toxicities, Version 1.2022 2022
    2022 Nonoperative Treatment of Large (5–7 cm), Node-Negative Non–Small Cell Lung Cancer Commonly Deviates From NCCN Guidelines 2022
    2021 Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphomaESMO Open.  6. 2021
    2021 A Phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignanciesClinical Cancer Research.  27:3050-3060. 2021
    2021 Management of acquired resistance to ALK inhibitors: Repeat biopsy to characterize mechanisms of resistance significantly impacts clinical outcomes 2021
    2021 Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials (Nature Reviews Clinical Oncology, (2021), 18, 5, (313-319), 10.1038/s41571-021-00487-z)Nature Reviews Clinical Oncology.  18:320. 2021
    2021 COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trialsNature Reviews Clinical Oncology.  18:313-319. 2021
    2021 Non-small cell lung cancer, Version 2.2021 featured updates to the NCCN guidelines 2021
    2020 Dose Escalation after RTOG 0617: Recent Trends and Predictors of Radiation Doses >70 Gy in Stage III Non-Small Cell Lung Cancer from the National Cancer Database 2020
    2020 Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLCJournal of Thoracic Oncology.  15:1705-1708. 2020
    2020 Survival is Worse in Patients Completing Immunotherapy Prior to SBRT/SRS Compared to Those Receiving it Concurrently or After 2020
    2020 Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesESMO Open.  5. 2020
    2020 Change in Reporting of USMLE Step 1 Scores and Potential Implications for International Medical Graduates 2020
    2019 Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade 2019
    2019 Activity of brigatinib in crizotinib and ceritinib-resistant ROS1- rearranged non-small-cell lung cancer 2019
    2018 Co-relation of overall survival with peripheral blood-based inflammatory biomarkers in advanced stage non-small cell lung cancer treated with anti-programmed cell death-1 therapy: results from a single institutional databaseActa Oncologica.  57:867-872. 2018
    2018 Antibiotic use and overall survival in lung cancer patients receiving nivolumab.Journal of Clinical Oncology.  36:e15109-e15109. 2018
    2018 East Carolina University clinical experience study: Utilization of liquid biopsy to determine time to diagnosis and treatment in non-small cell lung cancer (NSCLC).Journal of Clinical Oncology.  36:e18519-e18519. 2018
    2018 Outcomes of immunomodulatory radiation strategies in combination with nivolumab compared with single agent nivolumab in lung cancer patients.Journal of Clinical Oncology.  36:e21134-e21134. 2018
    2018 Post- progression treatment patterns in advanced lung cancer patients treated with nivolumab.Journal of Clinical Oncology.  36:e21070-e21070. 2018
    2018 Stage III non-small cell lung cancer: Escalation matters, but how? 2018
    2018 Frailty: The missing piece of the pre-hematopoietic cell transplantation assessment?Bone Marrow Transplantation.  53:3-10. 2018
    2017 3A.01 Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti- PD-1 Therapy in Advanced Lung Cancer: A Retrospective AnalysisJournal of Thoracic Oncology.  12:S1556-S1557. 2017
    2017 OA03.05 Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival AnalysisJournal of Thoracic Oncology.  12:S1554-S1555. 2017
    2017 Incidence and impact of thromboembolic events in lung cancer patients treated with nivolumab.Journal of Clinical Oncology.  35:e20624-e20624. 2017
    2017 Sequence of stereotactic ablative radiotherapy and immune checkpoint blockade in the treatment of metastatic lung cancer.Journal of Clinical Oncology.  35:e20665-e20665. 2017
    2017 Outcomes of ERCC1 high locally advanced esophageal cancer patients treated with non-platinum vs platinum based CRT.Journal of Clinical Oncology.  35:192-192. 2017
    2016 PS01.64: Effect of Anti-PD1 Therapy on the Incidence of Thromboembolic Events in Lung CancerJournal of Thoracic Oncology.  11:S310-S311. 2016
    2016 The clinical significance of ebv DNA in the plasma and peripheral blood mononuclear cells of patients with or without ebv diseasesBlood.  127:2007-2017. 2016
    2012 Effects of Multiple Myeloma (MM) Therapy and Type of Thromboprophylaxis On the Incidence and Timing of Venous Thromboembolism (VTE) and Factors Predictive of VTE.Blood.  120:2244-2244. 2012
    2012 Incidence and characterization of venous thromboembolic events (VTE) in patients with pancreatic cancer: Effect of timing of VTE on survival.Journal of Clinical Oncology.  30:4037-4037. 2012

    Research Overview

  • Investigative therapeutics and Immune related adverse events
  • Investigator On

  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by CYTOSITE BIOPHARMA INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by REGENERON PHARMACEUTICALS, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by MIRATI THERAPEUTICS, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Private Grant  awarded by ELEVATION ONCOLOGY INC.
  • Private Grant  awarded by TOPALLIANCE BIOSCIENCES
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by I-MAB BIOPHARMA US LIMITED
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by CHECKMATE PHARMACEUTICALS INC
  • Private Grant  awarded by NAVIRE PHARMA INC
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by CYTOSITE BIOPHARMA INC
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by BRISTOL-MYERS SQUIBB COMPANY
  • Private Grant  awarded by CHECKMATE PHARMACEUTICALS INC
  • Private Grant  awarded by I-MAB BIOPHARMA US LIMITED
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. ^
  • Site-Specific Immune Cell Activation Detection for Improving Individualized Cancer Immunotherapy  awarded by NIH - OFFICE OF THE DIRECTOR
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), 2009
  • Full Name

  • Aparna Hegde